SYS-CON MEDIA Authors: Lori MacVittie, RealWire News Distribution, Cynthia Dunlop, Mark O'Neill, Kevin Benedict

News Feed Item

Healthcare Companies Report Board Changes, FDA Approvals, and Conference Call Schedules - Research Report on Quest Diagnostics, Supernus Pharma, Puma Biotechnology, Pacira, and ResMed

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 30, 2013 /PRNewswire/ --


Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), Puma Biotechnology, Inc. (NYSE: PBYI), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and ResMed Inc. (NYSE: RMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On December 24, 2013, Quest Diagnostics Inc.'s (Quest Diagnostics) stock reflected an increase of 0.83%, closing the day's trading session at $54.50. Over the past three trading days, the Company's stock increased 3.24%, compared to the Dow Jones Industrial Average Index, which gained 1.10% during the same trading period. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ba_DGX

--

Supernus Pharmaceuticals, Inc. Research Report  

On December 24, 2013, Supernus Pharmaceuticals, Inc. (Supernus) announced that Michael Bigham, a General Partner at Abingworth has resigned from the Company's Board of Directors, effective December 23, 2013. Commenting on the resignation, Michael Bigham stated, "Abingworth remains a significant shareholder in Supernus but as a matter of general practice we limit the time we spend on the boards of our portfolio companies once they have become public companies." Jack Khattar, CEO, President and Director of Supernus, added, "Since joining the Supernus Board of Directors in 2006, Michael Bigham has been a great contributor providing the Board with great insight and judgment based on his vast experience in the healthcare industry. We will miss him, and are grateful for his service." In other news dated, December 23, 2013, Supernus reported that FDA has approved Orenitram™ (treprostinil), Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. The Full Research Report on Supernus Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ccb_SUPN

--

Puma Biotechnology, Inc. Research Report

On December 24, 2013, Puma Biotechnology, Inc.'s (Puma Biotechnology) stock gained 7.24%, closing the day's trading session at $110.10. The Company's stock increased 9.77% over the past three trading days, compared to the S&P500 Index, which ended 1.31% higher during the same trading period. The Full Research Report on Puma Biotechnology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4d27_PBYI

--

Pacira Pharmaceuticals Inc. Research Report

On December 24, 2013, Pacira Pharmaceuticals Inc.'s (Pacira) stock edged up 1.02%, closing the day's trading session at $56.50. The Company's stock gained 14.47%, over the past three trading days, compared to the Nasdaq composite Index, which ended 2.40% higher during the same trading period. The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c0aa_PCRX

--

ResMed Inc. Research Report

On December 18, 2013, ResMed Inc. (ResMed) announced that the Company will release its Q2 FY 2014 and H1 FY 2014 financial results (period ending December 31, 2013), on Thursday, January 23, 2014 after 1:00 p.m. U.S PT. Additionally, the Company stated that it will host a conference call, beginning at 1:30 p.m. U.S PT, to review its results market trends, and future outlook. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bd44_RMD

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.